The association between the copy‐number variations of ZMAT4 and hematological malignancy

Figures & data

Table 1. CNVs of ZMAT4 in controls and hematological malignancies

		Copy numbers
CNVs, population	No. of subjects	Deletion			Amplification		P (versus control)	P (versus AML)	P (versus ALL)	P (versus CML)
		0	1	2	3	>3
Control	102	0	5	96	1	0	…	…	…	…
AML	114	4	28	67	14	1	1·9×10^−7	…	…	…
M2	47	2	17	21	7	0	3·1×10^−10	…	…	…
M5	17	0	4	13	0	0	2·5×10^−2	…	…	…
APL	22	2	5	12	2	1	7·1×10^−6	…	…	…
Others	28	0	2	21	5	0	6·6×10^−4	…	…	…
ALL	86	0	11	54	16	5	8·1×10^−7	1·8×10^−2	…	…
CML	78	0	32	39	7	0	1·1×10^−10	0·0735	1·1×10^−4	…
CLL	72	0	31	41	0	0	6·2×10^−9	2·1×10^−3	7·3×10^−7	3·3×10^−2
MM	67	0	13	54	0	0	8·8×10^−3	5·4×10^−3	2·6×10^−4	2·4×10^−4
MDS	98	2	43	53	0	0	7·5×10^−10	6·6×10^−4	2·3×10^−8	1·4×10^−2

Note: CNVs, copy number variants; AML, acute myelogenous leukemia; APL, acute promyelocytic leukemia; ALL, acute lymphoblastic leukemia; CML, chronic myelogenous leukemia; MM, multiple myeloma; CLL, chronic lymphocytic leukemia; MDS, myelodysplastic syndrome.

Figure 1. Expression of ZMAT4 mRNA in samples with 1 or 2 copies of DNA. The relative expression level of ZMAT4 mRNA was calculated by using the comparative C(T) method with RNAse P as the internal control. Fold change of each sample was calculated as follows: fold change = relative expression level/average expression level in the group with 2 copies of DNA. Y axis indicates the number of samples in each level of fold change. P value was calculated by chi‐square test.